{"doc_id": "si-2023-0200-reg-1", "parent_doc_id": "si-2023-0200", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 200 of 2023", "title": "Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act", "year": 2023, "heading": "1. These Regulations may be cited as the Misuse Of Drugs (Prescription", "text_raw": "1. These Regulations may be cited as the Misuse Of Drugs (Prescription \nAnd Control Of Supply Of Cannabis For Medical Use) (Amendment) (No. 2) \nRegulations 2023. \n\nDefinitions", "text_norm": "1 regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) (no 2) regulation 2023 definition", "start_char": 680, "end_char": 858, "source_path": "downloads\\2023\\2023_0200.pdf", "extraction_method": "pdfminer", "checksum": "sha256:532cfcdaa1a851dc502b6162d6c28a148c563432839885e85595334c86929087", "cross_refs": []}
{"doc_id": "si-2023-0200-reg-2", "parent_doc_id": "si-2023-0200", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 200 of 2023", "title": "Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act", "year": 2023, "heading": "In these Regulations –", "text_raw": "2. \n\nIn these Regulations – \n\n“Principal Regulations” means the Misuse of Drugs (Prescription and Control \nof Supply of Cannabis for Medical Use) Regulations 2019 (S.I. No. 262 of \n2019), as amended by the Misuse of Drugs (Prescription and Control of Supply \nof Cannabis for Medical Use) (Amendment) Regulations 2019 (S.I. No. 583 of \n2019), the Misuse of Drugs (Prescription and Control of Supply of Cannabis \nfor Medical Use) (Amendment) Regulations 2019 (S.I. No. 649 of 2019), the \nMisuse of Drugs (Prescription and Control of Supply of Cannabis for Medical \nUse) (Amendment) Regulations 2020 (S.I. No. 505 of 2020), the Misuse of \nDrugs (Prescription and Control of Supply of Cannabis for Medical Use) \n(Amendment) Regulations 2021 (S.I. No. 557 of 2021), the Misuse of Drugs \n(Prescription and Control of Supply of Cannabis for Medical Use) \n(Amendment) Regulations 2022 (S.I. No. 237 of 2022) and the Misuse Of \nDrugs (Prescription and Control of Supply of Cannabis for Medical Use) \n(Amendment) Regulations 2023 (S.I. No. 5 of 2023). \n\nAmending the Principal Regulations", "text_norm": "2 regulation - principal regulation mean misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019) amended misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2019 (s.i no 583 2019) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2019 (s.i no 649 2019) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2020 (s.i no 505 2020) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2021 (s.i no 557 2021) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2022 (s.i no 237 2022) misuse drug (prescription control supply cannabis medical use) (amendment) regulation 2023 (s.i no 5 2023) amending principal regulation", "start_char": 858, "end_char": 1939, "source_path": "downloads\\2023\\2023_0200.pdf", "extraction_method": "pdfminer", "checksum": "sha256:532cfcdaa1a851dc502b6162d6c28a148c563432839885e85595334c86929087", "cross_refs": []}
{"doc_id": "si-2023-0200-reg-3", "parent_doc_id": "si-2023-0200", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 200 of 2023", "title": "Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act", "year": 2023, "heading": "3. The Principal Regulations are amended by substituting for Schedule 1", "text_raw": "3. The Principal Regulations are amended by substituting for Schedule 1 \n\nthe following: \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 2nd May, 2023. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[200] 3 \n\nRegulation 2 \n\n“SCHEDULE 1 \n\nSpecified Controlled Drugs \n\nName of \nCannabis \nproduct or \npreparation \nand \nbrand name \n\nAurora High \nCBD Oil Drops \n\nDosage form Concentration of THC \n\nName of \n\n(percentage, \n\nmanufacturer \n\nweight/weight or \n\nweight/volume) \n\nOral solution Less than 3% w/v (< \n\nAurora Cannabis \n\n30mg/ml) This product \n\nEnterprises Inc., \n\nalso contains \n\n4439 Township \n\ncannabidiol (CBD) 60% \n\nRoad 304, \n\nw/v (600mg/ml) \n\nCremona, \n\nCannEpil ™ \n\nOral solution 0.5% w/v (5mg/ml) \n\nThis product also \n\ncontains cannabidiol \n\nAlberta, Canada, \n\nT0M 0R0 \n\nMGC \nPharmaceuticals \nd.o.o., Kamniška \nulica 29, 1000, \n\nTilray Oral \nSolution \nTHC10:CBD10 \n(25ml) \n\n(CBD) 10% w/v \n\n(100mg/ml) \n\nLjubljana, \n\nSlovenia \n\nOral solution 1% w/v (10mg/ml) \n\nTilray Portugal \n\nThis product also \ncontains cannabidiol \n(CBD) 1% w/v \n(10mg/ml) \n\nUnipessoal Lda., \n\nZona Industrial \n\nde Cantanhede, \n\nLote 121, \n\nCantanhede, \n\n3060-197, \n\nPortugal \n\nAurora \nSedamen \nSoftgels \n\nCapsules \n\n5mg/capsule This \n\nAurora Cannabis \n\nproduct also contains \n\nEnterprises Inc. \n\ncannabidiol (CBD) less \n\n4250 14th \n\n \n \n \n \n\f4 [200] \n\nthan 0.2mg/capsule \n\nAvenue, \n\nMarkham, \n\nOntario, Canada \n\nL3R 0J3 \n\nOleo \n\nDried flower 13.5% w/w (135mg/g) \n\nBureau voor \n\nBedrobinol \n\nMedicinale \n\nThis product also \n\nCannabis Postbus \n\ncontains cannabidiol \n\n16114 2500 BC \n\n(CBD) less than 1.0% \n\nDEN HAAG The \n\nw/w (less than 10mg/g) \n\nNetherlands \n\nOleo Bedrocan Dried flower 22% w/w (220mg/g) \n\nBureau voor \n\nAlthea \nCBD12:THC10 \n(50ml) \n\nMedicinale \n\nThis product also \n\nCannabis Postbus \n\ncontains cannabidiol \n\n16114 2500 BC \n\n(CBD) less than 1.0% \n\nDEN HAAG The \n\nw/w (less than 10mg/g) \n\nNetherlands \n\nOil \n\n1% w/v THC (10mg/ml) \n\nTasmanian \n\nAlkaloids pty Ltd \n\nThis product also \n\nT/A Extractas \n\ncontains 1.25% w/v \n\nBioscience, \n\n(12.5mg/ml) \n\nWestbury, \n\ncannabidiol (CBD) \n\nTasmania, \n\nAustralia 7303 \n\nOleo Genetics \n10:10 \n\nOil (oral \n\n1% w/v (10mg/ml) \n\nADREX Pharma \n\nsolution) \n\nGmbH \n\nThis product also \n\nFirmungstrabe 4 \n\ncontains cannabidiol \n\n56068 Koblenz \n\n(CBD) 1% w/v \n\nGermany \n\n(10mg/ml) \n\nOleo Genetics \n\nOil (oral", "text_norm": "3 principal regulation amended substituting schedule 1 following notice making statutory instrument published iris oifigiuil 2nd may 2023 200 3 regulation 2 schedule 1 specified controlled drug name cannabis product preparation brand name aurora high cbd oil drop dosage form concentration thc name (percentage manufacturer weight weight weight volume) oral solution le 3 w v ( aurora cannabis 30mg ml) product enterprise inc also contains 4439 township cannabidiol (cbd) 60 road 304 w v (600mg ml) cremona cannepil (tm) oral solution 0.5 w v (5mg ml) product also contains cannabidiol alberta canada t0m 0r0 mgc pharmaceutical d.o.o kamniska ulica 29 1000 tilray oral solution thc10 cbd10 (25ml) (cbd) 10 w v (100mg ml) ljubljana slovenia oral solution 1 w v (10mg ml) tilray portugal product also contains cannabidiol (cbd) 1 w v (10mg ml) unipessoal lda zona industrial de cantanhede lote 121 cantanhede 3060-197 portugal aurora sedamen softgels capsule 5mg capsule aurora cannabis product also contains enterprise inc cannabidiol (cbd) le 4250 14th 4 200 0.2mg capsule avenue markham ontario canada l3r 0j3 oleo dried flower 13.5 w w (135mg g) bureau voor bedrobinol medicinale product also cannabis postbus contains cannabidiol 16114 2500 bc (cbd) le 1.0 den haag w w (less 10mg g) netherlands oleo bedrocan dried flower 22 w w (220mg g) bureau voor althea cbd12 thc10 (50ml) medicinale product also cannabis postbus contains cannabidiol 16114 2500 bc (cbd) le 1.0 den haag w w (less 10mg g) netherlands oil 1 w v thc (10mg ml) tasmanian alkaloid pty ltd product also extractas contains 1.25 w v bioscience (12.5mg ml) westbury cannabidiol (cbd) tasmania australia 7303 oleo genetics 10 10 oil (oral 1 w v (10mg ml) adrex pharma solution) gmbh product also firmungstrabe 4 contains cannabidiol 56068 koblenz (cbd) 1 w v germany (10mg ml) oleo genetics oil (oral", "start_char": 1939, "end_char": 4300, "source_path": "downloads\\2023\\2023_0200.pdf", "extraction_method": "pdfminer", "checksum": "sha256:532cfcdaa1a851dc502b6162d6c28a148c563432839885e85595334c86929087", "cross_refs": []}
{"doc_id": "si-2023-0200-reg-2", "parent_doc_id": "si-2023-0200", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 200 of 2023", "title": "Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act", "year": 2023, "heading": "2.5% w/v (25mg/ml)", "text_raw": "2.5% w/v (25mg/ml) \n\nADREX Pharma \n\n25:1 \n\nsolution) \n\nGmbH \n\nThis product also \n\nFirmungstrabe 4 \n\ncontains cannabidiol \n\n56068 Koblenz \n\n \n \n \n \n \n \n\f[200] 5 \n\n(CBD) <0.1% w/v \n\nGermany \n\n(<1mg/ml) \n\nAlthea \n\nOil \n\n2% w/v THC (20mg/ml) \n\nTasmanian \n\nTHC20:CBD1 \n\n(50ml) \n\nThis product also \ncontains <0.1% w/v \n(<0.1mg/ml) \ncannabidiol (CBD) \n\nAlkaloids pty Ltd \n\nT/A Extractas \n\nBioscience, \n\nWestbury, \n\nTasmania, \n\nAustralia 7303 \n\n”. \n\nGIVEN under my Official Seal, \n\n26 April, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [200]", "text_norm": "2.5 w v (25mg ml) adrex pharma 25 1 solution) gmbh product also firmungstrabe 4 contains cannabidiol 56068 koblenz 200 5 (cbd) 0.1 w v germany ( 1mg ml) althea oil 2 w v thc (20mg ml) tasmanian thc20 cbd1 (50ml) product also contains 0.1 w v ( 0.1mg ml) cannabidiol (cbd) alkaloid pty ltd extractas bioscience westbury tasmania australia 7303  given official seal 26 april 2023 stephen donnelly minister health 6 200", "start_char": 4300, "end_char": 4875, "source_path": "downloads\\2023\\2023_0200.pdf", "extraction_method": "pdfminer", "checksum": "sha256:532cfcdaa1a851dc502b6162d6c28a148c563432839885e85595334c86929087", "cross_refs": []}
{"doc_id": "si-2023-0200-explanatory-note", "parent_doc_id": "si-2023-0200", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 200 of 2023", "title": "Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Misuse of Drugs Act", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to update and replace the current Schedule \n1, in the Misuse of Drugs (Prescription and Control of Supply of Cannabis for \nMedical Use) Regulations 2019 (as amended) (“the Principal Regulations”), in \norder to include additional cannabis products or preparations for medical use as \n“specified controlled drugs”. \n\nThe purpose of the Principal Regulations is to allow additional cannabis \nproducts or preparations for medical use to be prescribed and supplied under \ncertain circumstances for the treatment of persons with certain medical \nconditions under the care of a medical consultant. \n\nThese Regulations may be cited as the Misuse of Drugs (Prescription and \nControl of Supply of Cannabis for Medical Use) (Amendment) (No. 2) \nRegulations 2023. \n\n \n \n \n \n \n \n \n\f[200] 7 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-476) 75. 4/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation update replace current schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (as amended) ( principal regulation ) order include additional cannabis product preparation medical use specified controlled drug  purpose principal regulation allow additional cannabis product preparation medical use prescribed supplied certain circumstance treatment person certain medical condition care medical consultant regulation may cited misuse drug (prescription control supply cannabis medical use) (amendment) (no 2) regulation 2023 200 7 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-476) 75 4 23 propylon", "start_char": 4875, "end_char": 6288, "source_path": "downloads\\2023\\2023_0200.pdf", "extraction_method": "pdfminer", "checksum": "sha256:532cfcdaa1a851dc502b6162d6c28a148c563432839885e85595334c86929087", "cross_refs": []}
